Join Jason Collins, Director of Process Architecture, and George Todorov, Sr. Process Engineer in Workshop I as they explain the approach taken to develop a facility program to manufacture allogeneic CAR-T therapy, automating and supporting the filling process in a 2-hour workshop at the CAR-TCR Summit.
Demand for cell and ex-vivo gene therapies is steadily increasing given the impressive efficacy of autologous CAR-T therapies against hematological malignancies. The reality of curative treatment and commercial approval of several autologous CAR-T products in recent years triggers developers to plan for increased capacity and treating larger patient populations. Pioneers in the CAR therapy space are also heavily investing in allogeneic platforms to create “off-the-shelf” therapeutic cells that are immediately available and can treat a large number of patients with a single product batch. This workshop will walk you through a case study exploring a commercial facility design IPS recently completed to enable our client’s late-stage clinical and commercial programs. The audience will gain an understanding of our approach to develop a facility program and true fit-for-purpose facility that will house allogeneic CAR therapy manufacturing, automated filling line and all supporting functions.
Details of the session include:
- Enhancing the potential for curative treatment and commercial approval for cell and ex-vivo gene and CAR-T therapies by increasing capacity to treat larger patient populations
- Walking through case studies exploring a commercial facility design IPS recently completed to enable client late-stage clinical and commercial programs
- Gaining an understanding of approach to develop a facility program and true fit-forpurpose facility that house allogeneic CAR therapy manufacturing, automated filling line and all supporting functions
For more information about the workshop and to register, visit the CAR-TCR Summit website.